| Literature DB >> 29296561 |
Yoo Kyoung Han1, Seo Yul Kim1, Jae Young Ahn1, Jin Ung Baek1.
Abstract
BACKGROUND: This study aimed to select prescriptions (mixtures of medicinal herbs) used in the treatment of bone and joint disorders in Korean medicine, and through the analysis of medicinal herb combination frequencies, select a high-frequency medicinal herb combination group for further experimental and clinical research.Entities:
Keywords: Bone disorder; Dongeuibogam (Dong yi bao gian); Text mining
Year: 2017 PMID: 29296561 PMCID: PMC5741390 DOI: 10.1016/j.imr.2017.09.001
Source DB: PubMed Journal: Integr Med Res ISSN: 2213-4220
Fig. 1First research step; establishing a list of PTBJDs and constituents of each item in “Dongeuibogam”.
PTBJD, prescription for the treatment of bone and joint disorder.
Fig. 2Second research step; selection of medicinal herb combinations from 64 PTBJDs in the order of frequency.
PTBJD, prescription for the treatment of bone and joint disorder.
Fig. 3Third research step; preliminary evaluation of the effects of CMHTBJDs via analysis of previous studies.
BJD, bone and joint disorder; CMHTBJD, candidates of a medicinal herb for the treatment of bone and joint disorder.
Sixty-four PTBJDs from “Dongeuibogam”
| Name of PTBJDs (No. of constituents) |
|---|
| Baifuzisan (8)/Baihuguizhitang (5)/Baozhentang (20)/Busundangguisan (7)/Butianwan (1)/Cangzhufujiandang (9)/Cangzhugao (2)/Chaijianmeiliansan (4)/Dafangfengtang (13)/Dajupitang (4)/Dancangzhuwan (1)/Dangguigao (18)/Digupisan (9)/Dingtongsan (12)/Dixiansan (5)/Duhuojishengtang (15)/Ermiaocangbaisan (2)/Ermiaosan (2)/Ershenggao (3)/Fuzitang (8)/Guntanwan (4)/Hugusan (12)/Huoxuesan (1)/Jiangusan (2)/Jiaweilonghusan (5)/Jiaweiqianghuotang (9)/Jiegudan (10)/Jiegusan (7)/Jieguzijindan (9)/Liuweidihuangyuan (6)/Lurongsijinwan (9)/Maidousan (6)/Maijiansan (11)/Manjingsan (9)/Meiyaojiangshengdan (9)/Qianghuoxuduantang (15)/Qianghuoyufengtang (27)/Qianjinzhimiwan (4)/Qinggusan (9)/Qingshenganluwan (8)/Qizhixiangfuwan (1)/Quanshenghugusan (7)/Renshenqingjisan (9)/Ruxiangdingtongwan (7)/Ruxiangheihudan (9)/Shengxisan (6)/Shenxianjijidan (22)/Tianmawan (10)/Tietanyuan (5)/Tuanyusan (6)/Weishengtianhuayuan (12)/Wubishanyaoyuan (12)/Wuwutang (3)/Wuzhengtang (9)/Wuzhengwan (7)/Wuzhuwan (5)/Xialingwanshoudan (5)/Xianyiliangtang (8)/Yiziqingjinsan (10)/Yuhangao (4)/Yuzhenwan (4)/Zirantongsan (12)/Ziyindabuwan (13) |
PTBJD, prescription for the treatment of bone and joint disorder.
Medicinal herb combinations from 64 PTBJDs in the order of frequency (80%)*
| No of constituents in each combination; name of constituents (frequency) |
|---|
| 1; E(13)/A(6)/D(4)/F(4)/G(4) |
| 2; A, D(4)/A, E(4)/C, D(3)/A, B(3)/A, C(3)/B, C(3)/B, D(3)/E, I (3)/B, E(3)/C, E(3)/E, G(3)/E, H(3)/D, E(3) |
| 3; A, D, E(3)/A, B, C(3)/A, B, D(3)/A, B, E(3)/B, C, D(3)/A, C, D(3)/B, D, E(3)/E, D, C(3)/A, C, E(3)/B, C, E(3) |
| 4; A, B, D, E(3)/A, B, C, D(3)/B, C, D, E(3)/A, C, D, E(3)/A, B, C, E(3) |
| 5; A, B, C, D, E(3) |
*Selecting CMHCTBJDs as the top five on the basis of frequency, only including frequencies >3, and including ties for 5th place.
CMHTBJD, candidates of a medicinal herb for the treatment of bone and joint disorder; PTBJD, prescription for the treatment of bone and joint disorder.
Fig. 4Number of previous studies on nine CMHTBJDs.
CMHTBJD, candidates of a medicinal herb for the treatment of bone and joint disorder.
Preliminary evaluation of the effects of nine CMHTBJDs in bone and joint disorder via analysis of the previous studies
| Name of CMHTBJD/classification of the study (No.)/source database/main outcome | ||
|---|---|---|
| VT (6) | (1) P/Prevents cartilage destruction in osteoarthritis & favor cartilage repair | |
| (2) P, S/Demonstrates inhibitory effects on RANKL-mediated osteoclast differentiation in bone marrow macrophages | ||
| (3) P/Inhibits IL-1β-induced rheumatoid synovial fibroblast proliferation & COX-2, PGE2, & MMPs production | ||
| (4) P/Stimulates UDP-sugar synthase genes through promoting gene expression of IGF-1 & IGF1R in chondrocytes | ||
| (5) P/Decreases the hydrogen peroxide-induced IL-1beta, TNF-alpha, MMP-1 & MMP-13 & increases SOX9 gene expression | ||
| (6) R/Shows inhibitory effect on osteoclast differentiation & function | ||
| VV (4) | (1) P/Less trabecular bone loss & thick cortical areas were observed | |
| (2) P/Prevents the OVX-induced bone loss in rats via estrogen-independent mechanism | ||
| (3) P/APS-3c can improve the proteoglycans synthesis of chondrocytes | ||
| (4) R, O/Has a suppressing inflammation effect on Freund‘s adjuvant arthritis in rats | ||
| RW (3) | (1) P, S/Has potent binding affinity with IL6R protein | |
| (2) P, S/Has strong antiinflammatory & antiarthritic effects | ||
| (3) R/Turns out to be the most frequently used herb for the treatment of osteoporosis since 2000 | ||
| VT (1) | (1) N, O, R/Has beneficial effect on osteoporosis by inhibition of osteoclast differentiation & by inhibition of functioning osteoclast | |
| VV (3) | (1) S/Increases the growth & differentiation of osteoblastic MC3T3-E1 cells | |
| (2) S/Inhibits osteoclast differentiation from its precursors | ||
| (3) N, R/Decreases the arthritic scores & inhibits pathological changes of knee joint tissues in CIA mice | ||
| RW (1) | (1) P/Consists one of the most used herbal drugs prescription cluster for osteoporosis treatment | |
| VV (1) | (1) N, R/Inhibits RANKL-induced osteoclast differentiation in bone marrow-derived macrophages | |
| RW (1) | (1) P, S, N/Triterpenoids are known to have a pivotal influence on rheumatoid arthritis | |
| VT (3) | (1) N, S/Reduces or prevents osteoblast degeneration in osteoporosis | |
| (2) S/Contributes to the prevention for osteoporosis | ||
| (3) R/May be useful as potential sources of therapeutic agents against postmenop- ausal osteoporosis | ||
| VV (6) | (1) P, N, S/Inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 & NF-κB pathway | |
| (2) N/Negatively regulates osteoclast differentiation & formation | ||
| (3) N, S/Suppresses inflammatory process by reducing the production of prostaglandin E2, leukotriene B4, nitric oxide, reactive oxygen species, proinflammatory cytokines & chemokines | ||
| (4) N, R/Relieves arthrocele & arthralgia & elevates the contents of L-ENK, beta-END, IL-2 & degrades the contents of SP, IgG, IL-1beta, IL-6 & inhibits abnormal secretion accentuation of synovial cell like fiber | ||
| (5) S/Inhibits abnormal proliferation of synoviocytes & treats the rheumatoid arthritis | ||
| (6) S/Total glucosides of paeony treats rheumatoid arthritis | ||
| RW(1) | (1) P/The beneficial effects of total glucosides of peony in treating rheumatoid arthritis were verified by randomized controlled trials | |
| VT (5) | (1) N, R, S/Has potential as a therapeutic material to attenuate the inflammatory disease such as rheumatoid arthritis | |
| (2) N/Contains active ingredients involved in bone tissue metabolism & may be effective in improving osteoporosis | ||
| (3) N, S/Improves the osteoporosis resulted from augmentation of osteoblast proliferation | ||
| (4) R/Shows remarkable inhibitive effect on RANKL-treated osteoclast differentiation without cytotoxicity | ||
| (5) P, N/Enhances the bone metabolism in osteoporosis | ||
| VV (4) | (1) N, R/Can be used for prevention & curing the postmenopausal obese | |
| (2) N, C, S/Controls rapid reduction of bone turnover in postmenopausal women | ||
| (3) P, S/Prevention of bone loss | ||
| (4) N, R/Decreases the serum level of cholesterol & increases the serum level of ALP | ||
| VT (4) | (1) P/Inhibits the IL-1β-induced expression of inflammatory mediators | |
| (2) P, N, R/Reduces the proliferation of human fibroblast-like synovial cells | ||
| (3) P/Potents inhibitory activities on bone resorption | ||
| (4) P/Potents inhibition against bone resorption | ||
| VV (6) | (1) P/Might prevent bone loss during aging & provide beneficial effects in osteoporosis in elderly people | |
| (2) P/Lies in the synchronous inhibitory effects on both the bone formation & the bone resorption | ||
| (3) N/Counteracts the progression of osteoporosis & augments bone mineral density | ||
| (4) P/Inhibits bone loss in bone mineral content | ||
| (5) P/Inhibits the decrease in cancellous bone mineral content, cancellous bone mineral density, & cortical bone mineral content | ||
| (6) N, O, R/Shows inhibitory effect on bone loss in osteoporetic condition, & reduces the increase of ALP activity & osteocalcin level in serum | ||
| Gypsum | VV (1) | (1) P/Improves amount, density & biomechanical performance of bone trabeculae in osteoporotic vertebra |
| VT (13) | (1) P/Promotes the differentiation of bone marrow mesenchymal stem cells & mononuclear cells into osteoblasts & osteoclast | |
| (2) P, S/Reduces receptor activator of nuclear factor kappa B ligand-induced tartrate-resistant acid phosphatase activity, pit formation (actin rings), & TRAP-positive multinucleated cells development in RAW264.7 cells | ||
| (3) P/Inhibits osteoclastogenesis by suppressing MAPK in LPS-activated RAW264.7 cells | ||
| (4) P, S/Plays an important therapeutic role in osteoporosis patients by improving osteogenic differentiation of Bone marrow stromal cells | ||
| (5) P/Has therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues such as those found in patients with arthritic disorders | ||
| (6) P/Protects the cell against the development of chondrocyte senescence in osteoarthritis | ||
| (7) P/Exerts a protective effect against the cartilage degradation of osteoarthritis | ||
| (8) P/Can be a potential alternative to the current antiTNF-alpha therapeutics for rheumatoid arthritis | ||
| (9) P, S/Reduces cell infiltration & cartilage destruction in the arthritic joint | ||
| (10) N, R/Has osteogenic & antiosteoclastogenesis properties & regards as potential therapeutic agents for management of osteoporosis | ||
| (11) N, R/Has beneficial effects against arthritis without any adverse effects | ||
| (12) S/Inhibits dexamethasone-induced apoptosis through promotion of GPR120 induction in bone marrow-derived mesenchymal stem cells | ||
| (13) R/Can be applicable for the improvement of arthritic symptoms as a new diet-supplement | ||
| VV (13) | (1) P/Prevents loss of cell viability caused by Dex-induced apoptosis in MC3T3E1 cells | |
| (2) P, S/The serum levels of TNF—a, IL—1β, & IL—6 were increased | ||
| (3) P/The bone-modulating effects of PNS may be due to the increased bone formation & decreased bone resorption | ||
| (4) P/Protects against bone loss in rat model by increasing the serum levels of TNF—α, IL—1β, & IL—6 | ||
| (5) P/Enhances bone mineral density, bone strength, & prevents the deterioration of trabecular microarchitecture without hyperplastic effect on uterus | ||
| (6) P, S/Can ameliorate arthritis in mice with CIA by targeting pathogenic Th17 & osteoclast differentiation | ||
| (7) P/Alleviates autoimmune arthritis by suppressing T cell activation | ||
| (8) N, R/Alternative medicine for the relief & prevention of rheumatoid arthritis symptoms | ||
| (9) S/Prevents postmenopausal bone loss by inhibiting osteoclast differentiation, a process controlled by estrogen | ||
| (10) S/Inhibits osteoclastogenesis by modulating NF-κB & MAPKs pathways | ||
| (11) S/Inhibits differentiation & maturation of osteoclasts | ||
| (12) S/Reduces the carrageenan-induced paw edema & suppresses the production of serum IL-6 | ||
| (13) P/The expression levels of chondrogenic genes, such as type II collagen & SOX9, were increased in the presence of ginsenoside Rb1 | ||
| RW (1) | (1) P, N, R, S/Most important therapeutic agent for the treatment of osteoporosis | |
| CS (1) | (1) P/Enhances the therapeutic effect in treating rheumatoid arthritis | |
| VT (2) | (1) P/Reduces the inflammatory responses in the joints of collagen-induced arthritis rats | |
| (2) N, R/Reduce osteoblast activity | ||
CMHTBJD, candidates of a medicinal herb for the treatment of bone and joint disorder; CS, Clinical study; C, Cochrane; N, Ndsl; O, Oasis; P, PubMed(); (), RW, Review; R, Riss; S, Scopus, VT, in vitro study, VV, in vivo study.